Introduction
Fc receptors (FcRs) are widely expressed on hemopoietic cells and are distinguished by their structure, function, distribution and ligands (IgG, IgM, IgE and IgA) (1) (2) (3) . Although FcRs have homologous extracellular immunoglobulin-like domains, there are functionally two types of FcRs: activating and inhibitory FcRs. Activating FcRs for IgG (FcγRs) play a central role in the efficacy of monoclonal antibody (mAb)-mediated therapy, which is mainly mediated by antibody-dependent cell-mediated cytotoxicity (ADCC) (1, 3) . Recent studies have shown that the inhibitory FcγR FcγRIIB also contributes to the therapeutic effects of treatment with agonistic mAbs (3, 4) . C-type lectin receptors, human dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) and murine DC-SIGN-related protein 1 (SIGN-R1) are also known to recognize sialylated Fc glycans of IgG; however, there are currently no data showing the contribution of these receptors in the efficacy of mAb therapies (2, 3) . Since the detailed structure and biology have already been described in previous articles, this review focuses on the consequences of human FcγR polymorphisms in mAb therapy.
FcR polymorphisms and copy-number variations
FcγR genes are known to have several single-nucleotide polymorphisms (SNPs), and numerous papers have suggested that polymorphisms in some of the activating FcγRs (FcγRIIA, FcγRIIIA and FcγRIIIB) and the inhibitory FcγRIIB are involved in susceptibility to autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) (5, 6) . In addition to SNPs, copy-number variations (CNVs) of FcγR genes are known to be associated with susceptibility to autoimmune disorders (6) (7) (8) (9) .
Most of the polymorphisms are located in the extracellular immunoglobulin-like domains that bind to IgG, thereby affecting the affinity between the FcγRs and IgG subclasses ( Fig. 1) (3, 6) .
There is currently no evidence of genetic variations in FcγRIA; however, functionally relevant polymorphisms and CNVs have been well investigated in other FcγRs (1, (5) (6) (7) 10) . FcγRIIA polymorphism has a point mutation of amino acid position 131, coding for arginine (R131) or histidine (H131) in the second immunoglobulin-like domain. FcγRIIA-H131 has a high affinity for human IgG3 and can bind to IgG2, whereas FcγRIIA-R131 barely binds to IgG2 (5, 6) . As an example of a functional effect, neutrophils carrying H/H131 homozygosity show a higher capacity for IgG2-mediated phagocytosis than those carrying an R/R131 genotype (11) . Regarding the genetic correlations between FcγRIIA and autoimmune diseases, high-affinity homozygous FcγRIIA-H/H131 is associated with Guillain-Barré syndrome (GBS) (12) , implying that immune complexes that include IgG auto-antibodies promote inflammatory responses. In contrast, the low-affinity FcγRIIA-R131 allele or an R/R131 genotype is associated with SLE, immune thrombocytopenic purpura (ITP) and IgA nephropathy (IgAN), suggesting that the attenuated clearance of immune complexes leads to autoimmune diseases (13) (14) (15) . Genome-wide association studies have provided novel understanding about the implication of FcγR polymorphisms in autoimmune diseases. It was reported that individuals carrying FcγRIIA-H131 show higher susceptibilities in Kawasaki disease and ulcerative colitis (16, 17) .
A polymorphism in the inhibitory FcγRIIB, which carries threonine at residue position 232 within the transmembrane domain (FcγRIIB-T232), has a single amino acid substitution from isoleucine (I) to threonine (T) (4) (5) (6) (7) 18) . It was shown that human monocytes transfected with 232T-FcγRIIB failed to inhibit FcγRI-mediated cellular activation because of impaired recruitment to sphingolipid rafts (19) . Several reports have shown that FcγRIIB-T/T232 is associated with disease susceptibility of SLE (4, 18, 20) . Other SNPs have been observed in the promoter region of FcγRIIB, which have -386G and -120T (haplotype 2B.2), and -386C and -120A (haplotype 2B.4) variants. The promoter haplotype 2B.4 SNP increases FcγRIIB expression on neutrophils and monocytes (13) . Haplotype 2B.4 was shown to be associated with susceptibility of SLE, whereas 2.B.4 haplotype negatively correlates with lupus nephritis (13) . Thus, further investigation is necessary for elucidation of the promoter SNPs in the disease association.
FcγRIIC has two kinds of polymorphisms in exon 3 of the gene: one encodes an open reading frame (ORF) allele (FcγRIIC-ORF) and another encodes a stop codon for glutamine at position 13 (FcγRIIC-Q13.STOP) (5-7). In addition, 20% of individuals carrying FcγRIIC-ORF lack FcγRIIC expression because of an additional mutation with a stop codon at exon 7 (FcγRIIC-ORF/Q13.STOP) (21) . FcγRIIC-ORF was shown to be expressed on NK cells from FcγRIIC-ORF individuals and FcγRIIC-ORF functions as an activating-type Fcγ receptor (21) . Individuals carrying FcγRIIC-ORF are known to have CNVs. CNVs in the FcγRIIC-ORF allele increased FcγRIIC-ORF expression, leading to the activation of NK cellmediated ADCC (21) . The FcγRIIC-ORF SNP is reported to be correlated with Kawasaki disease (22) , and CNVs of the FcγRIIC-ORF allele are also associated with ITP and SLE (6, 23, 24) . (12) , Kawasaki disease (16) , Ulcerative colitis (17) , Childhoodonset ITP (73) SLE (13) , ITP (14) , IgAN (15) , APS (74) SLE (13) (positive association), Lupus nephritis (13) (negative association) SLE (20) , Atopy (75) Kawasaki disease (22) IgAN (15) ,RA severity (30) , Childhood chronic ITP (73) SLE (25) , RA (26) , Crohn's disease (27) , Behcet's disease (28) , Severe GBS (29) IPF (31) , ANCAassociated disease (32) , Wegener's granulomat osis (32) Disease association (copy number variation)
ITP (23) , SLE (24) Anti-GBM disease (8) , Sarcoidosis (76) Glomerulonephritis (9) , SLE (9) , systemic sclerosis (9) , RA (33) , IPF (77) , Sarcoidosis (76) , Kawasaki disease (78) The FcγRIIIA polymorphism is a point mutation of amino acid position 158, encoding valine (V158) or phenylalanine (F158) in the membrane-proximal immunoglobulin-like domain (5-7). The FcγRIIIA-V158 genotype has a higher affinity for IgG1 and IgG4 than does the FcγRIIIA-F158 genotype (5, 6, 10) . The FcγRIIIA-F158 allele correlates with susceptibility to SLE, RA, Crohn's disease, Behçet's disease and GBS (25) (26) (27) (28) (29) , whereas V/V158 homozygosity is associated with the pathogenesis of RA (30) .
FcγRIIIB is a glycosylphosphatidylinositol-anchored receptor and consists of three alleles: FcγRIIIB-human neutrophil antigen (HNA)-1a, HNA-1b and HNA-1c (previously termed NA1, NA2 and SH, respectively) (5-7). FcγRIIIB-NA1, NA2 and SH each have five respective amino acid residues in the membrane-distal immunoglobulin-like domain: R36, N65, A78, D82 and V106; S36, S65, A78, N82 and I106; and S36, S65, D78, N82 and I106. FcγRIIIB-NA1, NA2 and SH comparably bind to IgG1 and IgG3 but not IgG2 and IgG4 (5-7, 10). Homozygous FcγRIIIB-NA1/NA1 is reported to be associated with idiopathic pulmonary fibrosis, anti-neutrophil cytoplasmic antibody (ANCA) associated disease and severe renal disease in granulomatosis with polyangiitis (Wegener's granulomatosis) (31, 32) . CNVs are also known to be associated with various autoimmune disorders (9) . Although the association between CNVs and RA is still controversial (9, 33) , the risk of SLE, Wegener's granulomatosis, primary Sjögren's syndrome and systemic sclerosis is increased in individuals with fewer gene copies (9) .
Basic mechanisms of antibody therapy
Recently developed immunotherapy using mAbs is expected to provide new therapeutic agents against cancer, allergy and autoimmune diseases (Table 1) . This is mainly due to advances in biotechnology, in which genetic engineering has developed recombinant humanized antibodies, thereby leading to the rapid advancement of mAb therapies (3, 34, 35 
Association of mAb therapies with FcR polymorphisms
Recently, targeted mAb therapies have made rapid progress in the treatment of cancers, including lymphoma and solid tumors. In particular, the therapeutic effects of IgG1 mAbs, such as rituximab and trastuzumab, are partially mediated by the FcγR-mediated immune response (ADCC), suggesting that polymorphisms of FcγRs may affect the potency of the mAb treatment. In this section, we present a brief synopsis of the effects of FcγRs on US Food and Drug Administration (FDA)-approved antibody therapies for lymphoma, for breast cancer, for colorectal cancer (CRC), as inhibitors of immunecheckpoint molecules, for autoimmune diseases and for allergic diseases (3, 34, 35) .
Antibody therapy against malignant lymphoma
Rituximab is one of the most advanced of these agents, earning FDA approval in 1997. Rituximab is a chimeric antibody that has the constant regions of human IgG1 fused to the variable regions of a mouse IgG1 mAb that targets the CD20 antigen, a four-transmembrane hydrophobic glycoprotein specifically expressed on B cells, such as pre-B cells and plasma cells (34, 36) . CD20 is positive in nearly 95% of cases of B-cell lymphoma and follicular lymphoma, and a combination of rituximab plus chemotherapy produces remarkable effects in patients with these lymphomas (34, 36) . The correlation between the FcγR genotype and the clinical outcomes of rituximab is controversial. Non-Hodgkin's lymphoma (NHL) patients with the FcγRIIIA-V158 genotype showed a slightly better response to rituximab than those with the FcγRIIIA-F158 genotype (37) . In addition, Asian NHL patients with the FcγRIIIA-V/V allele had a better response to rituximab therapy than those with the FcγRIIIA-F/F allele (38) . In contrast, NHL pediatric patients with the FcγRIIIA-F/F allele had a better response to rituximab treatment than those with the FcγRIIIA-V/V or V/F allele (39) and an examination of follicular lymphoma and chronic lymphocytic leukemia (CLL) patients treated with a combination of rituximab and chemotherapy revealed no association between the FcγR genotype and the clinical outcome (40) . As cells expressing FcγRIIIa-V/V efficiently exerted ADCC in an in vitro analysis, the response to rituximab is due in part to ADCC, but the association between the FcγR genotype and cytotoxicity in rituximab therapy is not yet clear (41, 42) . Patients with an increased expression of FcγRIIB on tumor cells have been shown to have a reduced survival or response to rituximab therapy because of the FcγRIIB-mediated internalization of CD20 (43) .
Tositumomab is a murine IgG2a monoclonal antibody targeting the CD20 antigen that is administered together with an iodine 131-labeled antibody (34) . The therapeutic effect of tositumomab is not correlated with FcγR genotypes (34) . However, the antibody was never approved for the Japanese market, and the approval of tositumomab was subsequently withdrawn in 2014.
Obinutuzumab is a humanized glycoengineered IgG1 antibody against the CD20 antigen that is modulated as a nonfucosylated oligosaccharide in the Fc region (34, 44) . Unlike rituximab, obinutuzumab eradicates tumor cells by augmenting ADCC and direct cell death, thereby reducing the complement-dependent cytotoxicity (CDC) (44) . Currently, the association of obinutuzumab-mediated outcomes with FcγR polymorphisms remains to be determined.
Ofatumumab is a fully humanized IgG1 anti-CD20 antibody, and the epitope recognized by this antibody is distinct from that of rituximab (34) . Ofatumumab has stronger binding to CD20 than rituximab does and exerts tumor cell killing activities via CDC and ADCC. A report showed no association of FcγRIIIA-158 polymorphisms with tumor cell depletion, but further studies are required to draw any conclusions regarding the relationship between these FcγR polymorphisms and the outcomes of antibody-based therapy (45) .
Alemtuzumab targets CD52, a glycoprotein that is expressed on malignant lymphocytes as well as peripheral lymphocytes but not on hemopoietic stem cells (34) . The main tumor-killing mechanism of alemtuzumab involves FcγRIII expression by NK cells and macrophages, which mediate ADCC and cross-linking-induced apoptosis (46, 47) . However, alemtuzumab therapy has no association with polymorphisms of FcγR and produces a number of side effects (48) .
Antibody therapy against breast cancer
Trastuzumab is a humanized monoclonal IgG1 antibody targeting human epidermal growth factor receptor 2 (HER2), a tyrosine-kinase receptor that regulates the cell growth and survival. HER2 is over-expressed on 30% of breast cancer cells and on other solid tumors, such as non-smallcell lung cancer (NSCLC) and ovarian and prostate cancer (49) . Several possible mechanisms by which trastuzumab mediates antitumor activity have been proposed (49) . One of the main therapeutic effects is to internalize the protein complex of trastuzumab-HER2 through FcγRs, resulting in the blockade of downstream signaling pathways involving tumor growth. Another important mechanism of trastuzumab actions is to induce ADCC and the response to trastuzumab treatment is significantly correlated with the ADCC activity (49) . Furthermore, a recent report showed an increase in numbers of cytotoxic T lymphocytes (CTLs) specific for HER2-expressing cancer cells, which may be because of the FcγR-mediated effective cross-presentation by dendritic cells (DCs) (50, 51) .
The correlation between FcγR genotypes and the pharmacological activity of trastuzumab is inconsistent. Indeed, several reports have described an association of FcγRIIA-H/ H131 and FcγRIIIA-V/V158 with the clinical outcomes (52) . However, a large analysis suggests that FcγRIIA-H/H is correlated with the clinical outcome of trastuzumab but FcγRIIIA-V/ V158 is not associated with the efficacy of trastuzumab (53) .
Antibody therapy against CRC
Cetuximab is a chimeric monoclonal IgG1 antibody against an epidermal growth factor receptor (EGFR) that binds to a site responsible for EGF binding (34) . Cetuximab is administered for the treatment of not only CRC but also head and neck cancer and NSCLC (34) . Cetuximab was originally produced to inhibit EGFR signaling, leading to a reduced cell growth and survival, but current data show the induction of ADCC to eliminate EGFR-expressing tumor cells (54) .
A report identified a positive correlation between FcγRIIA-H/H and FcγRIIIA-V/V polymorphisms and in vitro ADCC activity (55) . However, some studies have described the correlation of the FcγRIIA-H/H polymorphism alone with the therapeutic outcome (56) or the negative correlation of the FcγRIIA-V/V polymorphism with the clinical outcome (57) . Further studies are needed to determine the clinical association of FcγR polymorphisms with the efficacy of cetuximab.
Bevacizumab is a recombinant humanized IgG1 antibody directed against vascular endothelial growth factor A (VEGFA) and ramucirumab is a fully human IgG1 antibody directed against VEGF receptor 2 (VEGFR2), both of which work as angiogenesis inhibitors (34) . These antibodies are known to have no activity on ADCC (34) . Thrombosis was reported as a major adverse effect after bevacizumab and ramucirumab treatment (58) . Bevacizumab induces platelet activation and thrombosis through immune-complex formation with VEGF, which binds to FcγRIIA in mice transgenic for human FcγRIIA (59) . The association of FcγR polymorphisms with the clinical outcomes of bevacizumab and ramucirumab treatment has not yet been determined.
MAbs against immune-checkpoint inhibitors as cancer therapy
Antibodies that block inhibitory immune-checkpoint molecules are promising immunotherapeutics in cancer therapy. Nivolumab is a human anti-PD-1 IgG4 antibody used to treat melanoma, and pembrolizumab is a humanized anti-PD-1 IgG4 antibody used to treat melanoma and NSCLC, both of which exert clinical efficacy independent of FcRs (34, (60) (61) (62) .
Avelumab is a human anti-PD-L1 IgG1 antibody, and ipilimumab is a human anti-CTLA-4 IgG1 antibody, both of which mediate ADCC activity (60, 62, 63) . PD-L1 is known to be expressed on some tumor cells and myeloid-derived suppressor cells, and avelumab is likely to eliminate these cells by ADCC and NK cells with FcγRIIIA-V/V showing higher rates of lysis of tumor cells than those with FcγRIIIA-F/F (64). In addition, ipilimumab has been reported to mediate the lysis of CTLA-4-expressing T reg cells (65) . However, the association between FcR genotypes and the therapy outcomes of avelumab and ipilimumab is still poorly understood.
Antibody therapy for autoimmune diseases
Antibody-based therapies against autoimmune diseases depend on the potency of antibodies that are directed to pro-inflammatory cytokines or cytokine receptors, except for immunoglobulin Fc-fusion proteins (35) . The first antibody-based therapies against autoimmune diseases were anti-TNF-α antibodies (adalimumab and infliximab) for the treatment of RA. Infliximab is a chimeric anti-TNF-α IgG1 antibody composed of a murine variable region and a human constant region (66) . Adalimumab is a fully human anti-TNF-α IgG1 antibody. Infliximab and adalimumab bind to TNF-α, thus preventing binding to TNF-α receptors and resulting in a reduced inflammatory response (66) . In addition, the immune complexes formed with these antibodies and TNF-α bind to the type 2 TNF receptor, leading to apoptosis of TNF-α-expressing effector cells. Furthermore, these antibodies and golimumab, which is a human anti-TNF-α IgG1 antibody, exert cytotoxicity by binding to transmembrane TNF-α on target cells (67, 68) .
Previous studies have shown a correlation between adalimumab and infliximab and FcγRIIA-H/H, which has a higher affinity for the mAbs than FcγRIIA-R/R does, in RA treatment. Despite the small population of RA patients, FcγRIIIA-F/F polymorphism correlated with the therapeutic outcomes of treatment with anti-TNF-α agents (69, 70) .
Tocilizumab (Actemra) is a humanized anti-IL-6 receptor IgG1 antibody that has shown efficacy in treating RA (71) , but the association of tocilizumab therapy with FcR polymorphisms remains poorly understood.
Antibody therapy for allergic diseases
Antibody-based therapy targeting IgE in bronchial asthma has been applied in a clinical setting in Europe and the USA. Omalimumab is a humanized IgG1 mAb directed at human IgE that consists of a mouse-derived complementary determining region responsible for IgE binding and human variable and constant regions. Omalimumab is used to treat allergic rhinitis and atopic asthma and ameliorates symptomatic states by reducing the circulating concentration of IgE (72) .
The proposed mechanisms of omalimumab are (i) the abolition of binding of IgE to mast cells by sequestering soluble IgE, (ii) reducing FcεRI expression on the cell surface and (iii) binding to membrane IgE on B cells, leading to the suppression of B-cell differentiation into IgE-producing B cells (72) . The FcγRIIB-mediated inhibitory signal induced by the crosslinking of immunoglobulin binding to membrane IgE presumably induces the inhibition of differentiation into IgE-producing B cells (72) . However, the correlation of omalimumab with FcR polymorphisms has not yet been determined.
Conclusion
Targeted therapies with mAbs have improved the clinical efficacy of such treatments against cancer and autoimmune diseases (1-6, 35, 36) . mAb therapy is a representative treatment targeting FcRs, and most antibody-based therapies against cancer aim to enhance the ADCC activity mediated through activating-type FcγRs. As individual FcRs have a distinct affinity for certain immunoglobulins, the expression patterns of FcRs on effector cells affect the clinical outcomes of antibody therapies. Furthermore, current data show that FcR polymorphisms are also associated with the clinical efficacy of cancer treatment.
Further studies are needed to understand the correlation of antibodies used for treatment with the clinical outcomes in patients with various combinations of chemotherapy or other antibody therapies as well as in a variety of ethnicities.
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against immune-checkpoints are expected to undergo even further development for treating autoimmune diseases. FcR polymorphisms notably contribute to the pathogenesis of autoimmune diseases (1) (2) (3) (4) (5) (6) 36) . Additional studies are necessary to define how FcR polymorphisms affect the clinical outcomes of antibody therapy for the treatment of autoimmune diseases.
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